Doxycycline postexposure prophylaxis (doxy-PEP) reduces the risk of bacterial sexually transmitted infections among men who have sex with men and transgender women. In the United States, doxy-PEP is in an early stage of integration into clinical practice, and national guidelines for its use were recently released. The goal of this manuscript is to provide practical guidance for clinicians who are considering or currently prescribing doxy-PEP. We address 5 clinical questions using post hoc analyses of data from the DoxyPEP randomized controlled trial and discuss the potential implications and limitations of each question with the goal of informing clinical practice and implementation of doxy-PEP programs. The questions address patient eligibility criteria for doxy-PEP, the expected benefit and associated doxy-PEP doses for the average patient, the initial number of doses prescribed, and laboratory monitoring of persons taking doxy-PEP. This article addresses 5 clinical practice questions related to delivery of doxycycline postexposure prophylaxis for sexually transmitted infections in men who have sex with men and in transgender women using secondary data analyses from the DoxyPEP randomized controlled trial.
[1]Univ Washington, Dept Med, 325 9th Ave Box 359777, Seattle, WA 98104 USA.
[2]Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
[3]Publ Hlth Seattle & King Cty, HIV STI HCV Program, Seattle, WA USA.
[4]Fred Hutch Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA.
[5]Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA.
[6]Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[7]San Francisco Dept Publ Hlth, Populat Hlth Div, San Francisco, CA USA.
[8]Zuckerberg San Francisco Gen Hosp, Dept Med, San Francisco, CA USA.
(8.0+极速模式)